Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.

M Behnia, R Foster, L H Einhorn, J Donohue, C R Nichols

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m(2)) and cisplatin (20 mg/m(2)) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow
Original languageUndefined
Pages (from-to)472 - 475
JournalEuropean Journal of Cancer
Volume36
Issue number4
Publication statusPublished - 2000

Keywords

  • Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Germinoma/*drug therapy, Testicular Neoplasms/*drug therapy, Bleomycin/administration & dosage, Chemotherapy, Adjuvant, Cisplatin/administration & dosage, Drug Administration Schedule, Etoposide/administration & dosage, Follow-Up Studies, Germinoma/pathology, Germinoma/surgery, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Retrospective Studies, Testicular Neoplasms/pathology, Testicular Neoplasms/surgery

Cite this